• Publications
  • Influence
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improvedExpand
  • 3,036
  • 187
  • PDF
Strategies for multivessel revascularization in patients with diabetes.
BACKGROUND In some randomized trials comparing revascularization strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than percutaneous coronaryExpand
  • 1,336
  • 70
  • PDF
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independentExpand
  • 958
  • 53
Spironolactone for heart failure with preserved ejection fraction.
BACKGROUND Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone inExpand
  • 971
  • 34
  • PDF
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
BACKGROUND This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidneyExpand
  • 991
  • 31
  • PDF
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
Background— Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection fraction assigned toExpand
  • 506
  • 13
  • PDF
Treatment of anemia with darbepoetin alfa in systolic heart failure.
BACKGROUND Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinicalExpand
  • 347
  • 13
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
BACKGROUND In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced theExpand
  • 185
  • 13
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
BACKGROUND The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heartExpand
  • 372
  • 11
  • PDF
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugsExpand
  • 449
  • 10
  • PDF